|
Home : Unsafe Drugs : Keppra : Wikipedia : Levetiracetam Wikipedia - Levetiracetam
Levetiracetam (INN) (pronounced /lɛvɨtɪˈræsɨtæm/) is an anticonvulsant medication used to treat epilepsy.[1] It is the S-enantiomer of etiracetam, structurally similar to the prototypical nootropic drug piracetam. Levetiracetam is marketed under the trade name Keppra. Keppra is manufactured by UCB Pharmaceuticals Inc.
[edit] UsesAlong with other anticonvulsants like gabapentin, it is also sometimes used to treat neuropathic pain. Levetiracetam has recently been approved in the United Kingdom as a monotherapy treatment for epilepsy. It is also used in veterinary medicine for similar purposes. Levetiracetam has potential benefits for other psychiatric and neurologic conditions such as Tourette syndrome, autism, and anxiety disorder, but its most serious adverse effects are behavioral and its benefit-risk ratio in these conditions is not well understood.[2] [edit] Mechanism of ActionThe exact mechanism by which levetiracetam acts to treat epilepsy is unknown. However, the drug binds to a synaptic vesicle protein, SV2A,[3] which is believed to impede nerve conduction across synapses.[4] [edit] Side effectsSide effects include: hair loss; pins and needles sensation in the extremities; anxiety and psychiatric symptoms ranging from irritability to depression; and other common side effects like headache and nausea. Recent literature[5] suggests that the addition of pyridoxine (vitamin B6) may curtail some of the psychiatric symptoms. Levetiracetam is generally well tolerated[6] but may cause sleepiness, weakness, dizziness, and infection. In children, the most common side effects are sleepiness, accidental injury, hostility, irritability, and weakness. [7] [edit] References
[edit] External links
[edit] See also
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Levetiracetam". |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||




